The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Human Placenta Thioredoxin Reductase
Open accessAbstract
Human thioredoxin reductase is a pyridine nucleotide-disulfide oxidoreductase closely related to glutathione reductase but differing from the latter in having a Cys-SeCys (selenocysteine) sequence as an additional redox center. Because selenoproteins cannot be expressed yet in heterologous systems, we optimized the purification of the protein from placenta with respect to final yield (1-2 mg from one placenta), specific activity (42 units/mg), and selenium content (0.94 +/- 0.03 mol/mol subunit). The steady state kinetics showed that the enzyme operates by a ping-pong mechanism; the value of kcat was 3330 +/- 882 min-1, and the Km values were 18 microM for NADPH and 25 microM for Escherichia coli thioredoxin. The activation energy of the reaction was found to be 53.2 kJ/mol, which allows comparisons of the steady state data with previous pre-steady state measurements. In its physiological, NADPH-reduced form, the enzyme is strongly inhibited by organic gold compounds that are widely used in the treatment of rheumatoid arthritis; for auranofin, the Ki was 4 nM when measured in the presence of 50 microM thioredoxin. At 1000-fold higher concentrations, that is at micromolar levels, the drugs also inhibited human glutathione reductase and the selenoenzyme glutathione peroxidase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemistry and Biochemistry of Flavoenzymes
Muller, F. (2018) · CRC Press eBooks · doi:10.1201/9781351070577 · Cited by 1,214
[21] Thioredoxin and thioredoxin reductase
Holmgren, A., & Bjornstedt, M. (1995) · Methods in Enzymology · doi:10.1016/0076-6879(95)52023-6 · Cited by 941
Type I iodothyronine deiodinase is a selenocysteine-containing enzyme
Berry, M. J., Banu, L., & Larsen, P. R. (1991) · Nature · doi:10.1038/349438a0 · Cited by 883
Stadtman, T. C. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.000503 · Cited by 829
Rat liver thioredoxin and thioredoxin reductase: purification and characterization
Luthman, M., & Holmgren, A. (1982) · Biochemistry · doi:10.1021/bi00269a003 · Cited by 602
Tamura, T., & Stadtman, T. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1006 · Cited by 539
Gladyshev, V. N., Jeang, K. T., & Stadtman, T. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.6146 · Cited by 468
Laboratory-associated infections and biosafety
Sewell, D. L. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.3.389 · Cited by 364
Enzymatic Synthesis of Deoxyribonucleotides
Moore, E. C., Reichard, P., & Thelander, L. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)97743-4 · Cited by 340
Wakasugi, N., Tagaya, Y., Wakasugi, H., Mitsui, A., Maeda, M., Yodoi, J., & Tursz, T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8282 · Cited by 282
Cited by
Nordberg, J., & Arnér, E. S. J. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00724-9 · Cited by 2,662
Antioxidant defence mechanisms: From the beginning to the end (of the beginning)
Halliwell, B. (1999) · Free Radical Research · doi:10.1080/10715769900300841 · Cited by 1,020
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Ganther, H. E. (1999) · Carcinogenesis · doi:10.1093/carcin/20.9.1657 · Cited by 689
Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions
Arnér, E. S. J. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.014 · Cited by 673
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Hickey, J. L., Ruhayel, R. A., Barnard, P. J., Baker, M. V., Berners-Price, S. J., & Filipovska, A. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804027j · Cited by 599
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
The thioredoxin system in cancer
Arnér, E. S. J., & Holmgren, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.009 · Cited by 589
Regulated Protein Denitrosylation by Cytosolic and Mitochondrial Thioredoxins
Benhar, M., Forrester, M. T., Hess, D. T., & Stamler, J. S. (2008) · Science · doi:10.1126/science.1158265 · Cited by 546
Zhong, L., Arnér, E. S. J., & Holmgren, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100114897 · Cited by 527
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A., & Messori, L. (2010) · Medicinal Research Reviews · doi:10.1002/med.20168 · Cited by 503
Antioxidant Function of Thioredoxin and Glutaredoxin Systems
Holmgren, A. (2000) · Antioxidants & Redox Signaling · doi:10.1089/ars.2000.2.4-811 · Cited by 502
Gold compounds as therapeutic agents for human diseases
Berners-Price, S. J., & Filipovska, A. (2011) · Metallomics · doi:10.1039/c1mt00062d · Cited by 495
The thioredoxin system—From science to clinic
Gromer, S., Urig, S., & Becker, K. (2004) · Medicinal Research Reviews · doi:10.1002/med.10051 · Cited by 479
Self-citationTargeting the Thioredoxin System for Cancer Therapy
Zhang, J., Li, X., Han, X., Liu, R., & Fang, J. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.001 · Cited by 460
Zhong, L., & Holmgren, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000690200 · Cited by 427
Targeting the mitochondrial cell death pathway with gold compounds
Barnard, P. J., & Berners-Price, S. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.04.006 · Cited by 417
Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., & Rigobello, M. P. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.12.021 · Cited by 415
Substitution of the Thioredoxin System for Glutathione Reductase in Drosophila melanogaster
Kanzok, S. M., Fechner, A., Bauer, H., Ulschmid, J. K., Müller, H.-M., Botella-Munoz, J., Schneuwly, S., Schirmer, R. H., & Becker, K. (2001) · Science · doi:10.1126/science.291.5504.643 · Cited by 406
Self-citationThioredoxin reductase as a pathophysiological factor and drug target
Becker, K., Gromer, S., Schirmer, R. H., & Müller, S. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01703.x · Cited by 388
Self-citationKuntz, A. N., Davioud-Charvet, E., Sayed, A. A., Califf, L. L., Dessolin, J., Arnér, E. S. J., & Williams, D. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040206 · Cited by 365
Selenocysteine in proteins—properties and biotechnological use
Johansson, L., Gafvelin, G., & Arnér, E. S. J. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.05.010 · Cited by 352
Thioredoxin reductase: Two modes of catalysis have evolved
Williams, C. H., Arscott, L. D., Müller, S., Lennon, B. W., Ludwig, M. L., Wang, P., Veine, D. M., Becker, K., & Schirmer, R. H. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01702.x · Cited by 343
Self-citationOn the potential of thioredoxin reductase inhibitors for cancer therapy
Urig, S., & Becker, K. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.09.004 · Cited by 337
Self-citationAuranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
Harbut, M. B., Vilchèze, C., Luo, X., Hensler, M. E., Guo, H., Yang, B., Chatterjee, A. K., Nizet, V., Jacobs, W. R., Schultz, P. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504022112 · Cited by 330
Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductases
Sun, Q.-A., Wu, Y., Zappacosta, F., Jeang, K.-T., Lee, B. J., Hatfield, D. L., & Gladyshev, V. N. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.35.24522 · Cited by 323
The Thioredoxin System as a Therapeutic Target in Human Health and Disease
Mahmood, D. F. D., Abderrazak, A., El Hadri, K., Simmet, T., & Rouis, M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4757 · Cited by 305
Molecular Mechanism of Cellular Oxidative Stress Sensing by Keap1
Suzuki, T., Muramatsu, A., Saito, R., Iso, T., Shibata, T., Kuwata, K., Kawaguchi, S.-I., Iwawaki, T., Adachi, S., Suda, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.047 · Cited by 287
Poursaitidis, I., Wang, X., Crighton, T., Labuschagne, C., Mason, D., Cramer, S. L., Triplett, K., Roy, R., Pardo, O. E., Seckl, M. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.054 · Cited by 272
The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1
Cheff, D. M., Huang, C., Scholzen, K. C., Gencheva, R., Ronzetti, M. H., Cheng, Q., Hall, M. D., & Arnér, E. S. J. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102703 · Cited by 255
Du, Y., Zhang, H., Lu, J., & Holmgren, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.392225 · Cited by 230
Methylarsenicals and Arsinothiols Are Potent Inhibitors of Mouse Liver Thioredoxin Reductase
Lin, S., Cullen, W. R., & Thomas, D. J. (1999) · Chemical Research in Toxicology · doi:10.1021/tx9900775 · Cited by 230
Aon, M. A., Stanley, B. A., Sivakumaran, V., Kembro, J. M., O'Rourke, B., Paolocci, N., & Cortassa, S. (2012) · Journal of General Physiology · doi:10.1085/jgp.201210772 · Cited by 200
Selenius, M., Rundlöf, A.-K., Olm, E., Fernandes, A. P., & Björnstedt, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2884 · Cited by 170
Metadata
- Authors
- Gromer, S., Arscott, L. D., Williams, C. H., Schirmer, R. H., & Becker, K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1998-08
- Volume
- 273
- Issue
- 32
- Pages
- 20096-20101
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2008820074
- Cited by
- 536
- References
- 26
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.